Glyscend, Inc.
🇺🇸United States
A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Glyscend, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06259981
- Locations
- 🇺🇸
Sensible Healthcare, LLC, Ocoee, Florida, United States
🇺🇸Tampa Bay Medical Research, Inc., Clearwater, Florida, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Glyscend, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT05478525
- Locations
- 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
© Copyright 2025. All Rights Reserved by MedPath